氯环利嗪衍生物治疗丙型肝炎病毒感染的临床前药理学开发
本研究对廉价抗组胺药氯环利嗪进行先导优化,评估先导化合物的体外吸收、分布、代谢、排泄特性及体内药代动力学,筛选出新先导化合物,并在感染HCV的原代人肝细胞嵌合小鼠中评价疗效。
要点
- 氯环利嗪及其衍生物靶向HCV病毒进入环节。
- 对先导化合物进行了体外ADME特性和体内药代动力学评价。
- 在感染HCV的原代人肝细胞嵌合小鼠中评估了新先导化合物的疗效。
核心结论
- 进一步开发该化合物并将其纳入DAA方案,有潜力提高疗效、可负担性和可及性。
研究设计与样本
- 临床前研究:对氯环利嗪衍生物进行先导优化,评估体外吸收、分布、代谢、排泄特性及体内药代动力学,并在感染HCV的原代人肝细胞嵌合小鼠中评价疗效。
主要发现
- 筛选出新的先导化合物并在HCV感染的原代人肝细胞嵌合小鼠中进行了疗效评价。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) is a small, single-stranded, positive-sense RNA virus that infects more than an estimated 70 million people worldwide. Untreated, persistent HCV infection often results in chronic hepatitis, cirrhosis, or liver failure, with progression to hepatocellular carcinoma. Current anti-HCV regimens comprising direct acting antivirals (DAAs) can provide curative treatment; however, due to high costs there remains a need for effective, shorter-duration, and affordable treatments. Recently, we disclosed anti-HCV activity of the cheap antihistamine chlorcyclizine, targeting viral entry. Following our hit-to-lead optimization campaign, we report evaluation of preclinical in vitro absorption, distribution, metabolism, and excretion properties, and in vivo pharmacokinetic profiles of lead compounds. This led to selection of a new lead compound and evaluation of efficacy in chimeric mice engrafted with primary human hepatocytes infected with HCV. Further development and incorporation of this compound into DAA regimens has the potential to improve treatment efficacy, affordability, and accessibility.
引用
- Rolt A, Le D, Hu Z, et al. Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Infect Dis. 2018. PMID: 29373739. doi:10.1093/infdis/jiy039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。